NDA 213026 · Sarepta Theraps INC
Amondys 45
Casimersen · Intravenous · Antisense Oligonucleotide
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Feb 25, 2021: To treat Duchenne muscular dystrophy
Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Feb 25, 2021
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat Duchenne muscular dystrophy
Therapeutic areas: Neurology · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Casimersen" as an intervention, any sponsor and status, largest first.
- Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)Pivotal-lookingCompleted
Sarepta Therapeutics, Inc.Industry
NCT02500381 · 228 participants · Start Sep 28, 2016 · Primary completion Nov 12, 2024
Drug: SRP-4045; SRP-4053 and 1 more · For: Duchenne Muscular Dystrophy
Sites: Phoenix, Arizona; Los Angeles, California; San Diego, California · 76 sites in all
- An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyPivotal-lookingTerminated
Sarepta Therapeutics, Inc.Industry
NCT03532542 · 171 participants · Start Aug 2, 2018 · Primary completion Jul 26, 2023
Drug: Casimersen; Golodirsen · For: Duchenne Muscular Dystrophy
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 50 sites in all
Sarepta Therapeutics, Inc.Industry
NCT02530905 · 12 participants · Start Oct 8, 2015 · Primary completion Oct 3, 2018
Drug: SRP-4045; Placebo · For: Duchenne Muscular Dystrophy
Sites: Los Angeles, California; Chicago, Illinois; Baltimore, Maryland
Kevin FlaniganAcademic, hospital or other
NCT04179409 · 3 participants · Start Feb 18, 2020 · Primary completion Sep 1, 2021
Drug: Amondys 45; Exondys 51 and 1 more · For: Duchenne Muscular Dystrophy
Sites: Columbus, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Amondys-45 (Casimersen)
2024 spending
$14.1M
Beneficiaries
n/a
185 claims
Per beneficiary
n/a
$818.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $4,432,004 |
| 2022 | $10,009,061 |
| 2023 | $13,621,714 |
| 2024 | $14,095,203 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, et al. · Drug Metab Dispos 2022 · Meta-Analysis, Review
- Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study.
Nicolau S, Malhotra J, Kaler M, et al. · J Neuromuscul Dis 2024 · Clinical Trial, Phase II
- Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
Wagner KR, Kuntz NL, Koenig E, et al. · Muscle Nerve 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD.
Tian C, Grabich S, Veerapandiyan A, et al. · J Comp Eff Res 2026 · Multicenter Study, Observational Study
Sponsor: Sarepta Theraps INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.